With So Many of Its Demands Met, How Will Industry Oppose Off-Year Price Revisions in FY2025?

Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The...read more